Research Overview
CJC-1295 with DAC is a synthetic 30-amino-acid analog of growth hormone releasing hormone (GHRH 1-29), modified at positions 2, 8, 15 and 27 (D-Ala, Gln, Ala, Leu) and conjugated to a Drug Affinity Complex (DAC). The DAC moiety binds circulating serum albumin, extending the plasma half-life of the molecule from minutes to approximately 6 to 8 days in published pharmacokinetic studies. The product is supplied as a lyophilized powder, 5mg per vial, sequence DAYSVQNYQQAHSK-NH2 modified GHRH(1-29) with DAC, molecular weight 3367.91 g/mol and purity verified by HPLC.
This material is intended strictly for in vitro laboratory research. CJC-1295 with DAC has been investigated in published research studying IGF-1 elevation models, growth hormone pharmacokinetic studies against unconjugated GHRH fragments and long-acting endocrine research systems. Researchers typically procure this compound to study prolonged GHRH receptor activation, downstream somatotropic axis dynamics and self-differentiated GH pulse architecture.
The compound is structurally distinct from short-acting GHRH analogs because of its serum albumin binding characteristics. This feature has made it useful in research focused on endocrine feedback mechanisms, long-duration exposure modelling and comparative investigations of GH release patterns. Documentation including Certificate of Analysis (CoA) and LCMS purity data is available upon request to verified research institutions.
Mechanism Studied in Research
CJC-1295 with DAC has been investigated as a GHRH receptor agonist that binds the pituitary somatotroph GHRH receptor coupled to adenylate cyclase pathways. The four amino acid substitutions and the Drug Affinity Complex modification substantially extend plasma residence time compared with native GHRH fragments.
Published studies have examined receptor activation, cAMP signalling, growth hormone secretion profiles and sustained IGF-1 elevation following administration. The DAC conjugation prolongs exposure, making it useful for research into endocrine feedback mechanisms and long-duration growth hormone signalling models.
Researchers have evaluated differences between DAC-conjugated and unconjugated GHRH analogs, focusing on secretion kinetics, receptor responsiveness and downstream endocrine markers. These investigations have contributed to the compound's widespread use in growth hormone physiology and metabolic signalling research.
Additional studies have explored pharmacokinetic behaviour, peptide stability and prolonged systemic exposure. The extended circulation profile remains one of the defining features that distinguishes CJC-1295 with DAC from shorter-duration GHRH analogs.
Research Applications
CJC-1295 with DAC has been investigated across several distinct research domains, each leveraging the compound's prolonged albumin-bound half-life and sustained GHRH receptor agonism.
In endocrine pharmacology research, the peptide has been studied to characterize growth hormone release patterns, IGF-1 regulation and long-acting peptide signalling. Researchers have examined weekly administration models and compared outcomes against shorter-acting GHRH analogs.
Metabolic and body-composition studies have evaluated the downstream consequences of sustained GH signalling, including investigations into lipid metabolism, glucose handling and endocrine adaptation pathways. The relatively long circulating half-life makes the compound useful when modelling prolonged receptor exposure.
Additional applications include pharmacokinetic modelling, receptor signalling research and comparative studies between DAC-conjugated and unconjugated GHRH formulations. Researchers also employ the compound in investigations examining somatotropic-axis regulation and hormone feedback systems.
Reconstitution Reference
CJC-1295 with DAC is supplied as a lyophilized powder, 5mg per vial. Reconstitution for laboratory use is performed with bacteriostatic water or another validated laboratory diluent depending on study requirements.
A frequently used research protocol introduces approximately 2.5mL of bacteriostatic water into the vial, producing a concentration suitable for common laboratory applications. The diluent should be added slowly down the inside wall of the vial to minimize peptide disruption and excessive foaming.
Researchers typically allow the solution to stand briefly until the powder has completely dissolved. The resulting solution should appear clear and free of visible particulates. Documentation of diluent volume, final concentration and preparation date is commonly maintained within laboratory records for traceability purposes.
Storage and Handling
Lyophilized CJC-1295 with DAC should be stored sealed at -20°C and protected from light and moisture. Under these conditions, the material maintains stability according to batch-specific documentation and laboratory storage protocols.
Following reconstitution, working solutions are commonly refrigerated at 2-8°C and used within established laboratory timelines. Researchers generally avoid repeated freeze-thaw cycles because repeated temperature fluctuations may contribute to peptide degradation and reduced experimental consistency.
Storage conditions, preparation dates, reconstitution volumes and handling procedures should be documented according to institutional laboratory practices. Any solution displaying discoloration, precipitation or visible particulate matter should be discarded and replaced with a freshly prepared sample.
References
[2] Teichman S. et al. (2006). Prolonged stimulation of growth hormone secretion by CJC-1295. Clinical Endocrinology. PMID 16430747
[3] Ionescu M. et al. (2006). Pharmacokinetic and pharmacodynamic profile of CJC-1295 with DAC. Journal of Clinical Pharmacology. PMID 16905656
[4] Modder U. et al. (2009). Sustained IGF-1 elevation following administration of CJC-1295. Growth Hormone & IGF Research. PMID 18537683
[5] Maheshwari H. et al. (2004). Evaluation of growth hormone releasing hormone analogs with prolonged activity. Journal of Clinical Investigation. PMID 15331398